Overview
Cellis is a European biotechnology company focused on cell-based cancer therapies. It develops therapeutic macrophages and a technology platform for generating a portfolio of oncology treatments.
Financials
Revenue history (in m)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 88 days for 2021). 2 of 6 audited by a statutory auditor.
- 202517/06/2026
- 202401/07/2025
- 202316/07/2024
- 202212/07/2023
- 202111/10/2022
- 202027/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Cellis Participated in the JLABS EMEA CEO Summit 2026 in London
Cellis was pleased to participate in the JLABS EMEA CEO Summit 2026 in London, represented by our CEO, Robert Aleksandrowicz, and our CSO, Prof. Magdalena
Cellis Showcases Macrophage-Based Cancer Therapy at the International Conference on Precision Medicine
Cellis was proud to participate in the International Conference on Precision Medicine and the STRIKE Scientific Meeting, held on 2–4 July 2026 in Messina,
Cellis secures FENG (NCBR) funding for glioblastoma therapy
Cellis has been awarded funding under the European Funds for a Modern Economy (FENG 2021–2027), administered by the National Centre for Research and
NCBR Recognizes Cellis Team for Award-Winning Glioblastoma Research
Cellis has been recognized by the National Centre for Research and Development (NCBR) following the announcement that research underlying the Macrophage-Drug
Pfizer Research Prize 2026 for Macrophage-Based Glioblastoma Therapy
We are pleased to announce that Cellis’ Macrophage-Drug Conjugate (MDC) platform has been awarded the Pfizer Research Prize 2026 in Oncology.
Cellis CEO to Speak in Copenhagen at EU Cancer Mission 2025
On 4 December 2025, leaders in oncology will gather in Copenhagen for the EU Cancer Mission conference “Advancing cancer care: personalised treatment and
Industry
Public procurement
Cellis is the contractor in one public sector contract, worth USD 1.14k.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Jul 24, 2026 | Supply of configured synuclein protein | $1,142 | Uniwersytet Warszawski |
Authorized Representatives
Manner of representation
The company is represented by each member of the management board independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Cellis Ag | 180 | $2,431.12 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2015-12-31.
96 1240 6074 1111 0011 6749 6530- 85 1240 6074 1111 0011 6749 6631
- 80 1240 6074 1111 0011 4962 9806
Debt
No entries in the National Debtors Register (KRZ).
Public aid
10 public aid cases recorded, with a total value of $11,188,520.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Apr 22, 2025 | Aid for research and development projects: experimental development | $1.5M$1,475,574 | Prezes Agencji Badań Medycznych | |
| Feb 6, 2025 | Aid for research and development projects: industrial research | $410.2K$410,208 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Feb 6, 2025 | Aid for research and development projects: experimental development | $156.7K$156,673 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
6 projects recorded: 4 from FE lists ($14,156,479) and 2 Commission grants (FTS) ($2,627,915).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-01-01 | Cellular therapy for pancreatic cancer | $5.6M$5,611,183 | European Funds for a Modern Economy | |
| 2024-12-01 | Innovative cell therapy for head and neck cancer | $4.1M$4,079,677 | European Funds for a Modern Economy | |
| 2022-11-01 | 101099232 - Macov - macrophage-based immunotherapy of platinum-resistant ovarian cancer | $2.1M$2,102,332 | 1.0.11 - Horizon Europe |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Receptonsp. z o.o. | $50,611.05 | receptonbiotech.com | ||
| Biostat Research and Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Biomedical Centerssp. z o.o. | $41,376.85 | biomedical-centers.com | ||
| Orphinic ScientificS.A. | $42,972.42 | orphinic.com | ||
| Target Cellssp. z o.o. | $41,315.36 | targetcells.pl | ||
| CannamedaiS.A. | $28,203.90 | cannamedai.com | ||
| InventroS.A. | $25,971.59 | inventro.co | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Scanomesp. z o.o. | $12,895.57 | scanome.com | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-10-29 | Address change (Ul. Gen. Józefa Zajączka 28, 01-510, Warszawa → Ul. Gen. Józefa Zajączka 26, 01-510, Warszawa) | |
| 2018-06-21 | Share capital increase (8,700.00 PLN → 9,000.00 PLN) | |
| 2017-11-20 | Share capital increase (8,200.00 PLN → 8,700.00 PLN) | |
| 2017-05-31 | Share capital increase (7,500.00 PLN → 8,200.00 PLN) | |
| 2016-06-15 | Share capital increase (6,450.00 PLN → 7,500.00 PLN) |
FAQ
Last updated: 2026-10-07